BlueRyan, I know I guess I didn't word that well enough on my post. I was actually in between surgeries when I posted that. I'm a vet so I'm very familiar with their products.
Biotech and I are on the same page, I think Galliprant is a great product, I have a few patients on it that I can't use other meds on and it's great for that. However it's very expensive compared to other NSAIDs. I work at a high end clinic in a very wealthy area and still have clients that don't want to make the switch because of the cost. Cost is always a huge factor in veterinary medicine that is not an issue in human medicine. The price will come down with time but Galliprant is moving slow off my shelves right now. Big brother is pushing it hard but from myself and other vets I've spoke to we all see the same thing, very slow sales.
Same thing with Entyce, i actually don't even stock it as I have other appetite stimulants that work great that have been used for years and years and are dirt cheap.
Not nocking any of their products, I'm just saying with the pricing and my experience in the vet industry I don't think there's going to be a big price surge for Aratana anytime soon and I don't think a buyout is going to be anytime soon either. I think Aratana is long term play but short term expect it to stay around this range for a while and probably dip back down before it makes another step up again.
Sam
